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Abstract
Nerve growth factor (NGF) signaling is important in the development and functional maintenance of nociceptors, but it also plays a
central role in initiating and sustaining heat and mechanical hyperalgesia following inflammation. NGF signaling in pain has tradition-
ally been thought of as primarily engaging the classic high-affinity receptor tyrosine kinase receptor TrkA to initiate sensitization
events. However, the discovery that secreted proforms of nerve NGF have biological functions distinct from the processed mature
factors raised the possibility that these proneurotrophins (proNTs) may have distinct function in painful conditions. ProNTs engage a
novel receptor system that is distinct from that of mature neurotrophins, consisting of sortilin, a type I membrane protein belonging
to the VPS10p family, and its co-receptor, the classic low-affinity neurotrophin receptor p75NTR. Here, we review how this new
receptor system may itself function with or independently of the classic TrkA system in regulating inflammatory or neuropathic pain.
Introduction
The neurotrophin family consists of the founding member nerve
growth factor (NGF), brain-derived neurotrophic factor (BDNF),
neurotrophin-3, and neurotrophin-4 (NT-4). The mature forms of the
neurotrophins all interact with their respective high-affinity tropomy-
osin kinase receptors (TrkA, NGF; TrkB, BDNF and NT-4; and
TrkC, neurotrophin-3) but also bind to the low-affinity p75 neurotro-
phin receptor (p75NTR; Chao, 2003; Skeldal et al., 2011). Neuro-
trophin signaling is extremely important for the development of the
peripheral nervous system (Lewin & Barde, 1996), including the
specification of neuronal diversity (Lewin, 1996), and is also critical
in regulating synaptic plasticity (Greenberg et al., 2009; Park &
Poo, 2013). Of the four neurotrophic factors, NGF plays a central
role in the genesis of post-inflammatory pain hypersensitivity.
Indeed, in the last 20 years the link between the biology of NGF
and pain has become very well established (Heppenstall & Lewin,
2000; Pezet & McMahon, 2006; Mantyh et al., 2011). Several
major pharmaceutical companies are running clinical trials of
humanized antibodies designed to sequester NGF for the treatment
of pain in conditions as varied as osteoarthritis, lower back pain,
and interstitial cystitis (Cattaneo, 2010; Lane et al., 2010; Evans
et al., 2011a; Brown et al., 2012, 2013). The mechanism of action
of anti-NGF drugs has been predicated on the basis that NGF
sequestration primarily reduces signaling through TrkA receptors on
nociceptive sensory neurons. Over 10 years ago, a new level of
complexity in neurotrophin signaling arrived with the discovery that
secreted proforms of the neurotrophins NGF (proNGF) and BDNF
(proBDNF) have biological functions distinct from those of the
processed mature factors (Lee et al., 2001; Teng et al., 2005).
Proneurotrophins (proNTs) were shown to actually initiate apoptosis
in sympathetic neurons, and induce synaptic long-term depression
and growth cone collapse of hippocampal neurons by binding to
p75NTR (Lee et al., 2001; Woo et al., 2005; Martinowich et al.,
2007; Deinhardt et al., 2011). Later, it was shown that sortilin, a
type I membrane protein belonging to the VPS10p family, is a an
essential co-receptor for p75NTR that is required for proNT to
engage p75NTR with high affinity and transmit the apoptotic signal
(Nykjaer et al., 2004; Jansen et al., 2007; Skeldal et al., 2012). As
an NGF signaling axis is essential in the etiology of pain and hyper-
algesia, it is also of interest to understand how proNT signaling
might fit into the well-characterized nociceptive pathways that are
controlled by NGF. Here, we review the mechanistic basis of how
NGF functions in nociception and chronic pain, and discuss how
proNT signaling may fit into the biology of NGF-dependent pain.
proNTs
It has long been known that neurotrophins are first produced as
proforms that are processed by proteolytic cleavage to the mature
secreted forms (Teng et al., 2010). There is now abundant evidence
that, under physiological conditions, proNTs exit the cell and engage
a distinct receptor complex consisting of p75NTR and sortilin that
can initiate cell death, especially in cases of neuronal trauma or stress
(Jansen et al., 2007; Nykjaer & Willnow, 2012). The p75NTR–sorti-
lin receptor complex engaged by proNTs essentially initiates the
opposite signal (death vs. survival) to that of the classic high-affinity
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Trk receptors, which are receptor tyrosine kinases (Lewin & Barde,
1996; Reichardt, 2006). Importantly, the data in the literature have
mostly shown that proNTs do not activate Trk receptors directly
(Boutilier et al., 2008; Howard et al., 2013). However, as in all sig-
naling events initiated by secreted ligands, the cellular response may
be very dependent on the repertoire of receptors available and the cel-
lular context. For example, it is known that, in cells lacking p75NTR,
the affinity and specificity of neurotrophin signaling via their cognate
Trk receptors is much reduced (Chao, 2003). Thus, the potential
signaling events in cells responding to proNGF will depend on the
complement of cell surface receptors available. In this context, it is
important to note that p75NTR is known to be expressed by approxi-
mately half of all sensory neurons (Lee et al., 1992; Arnett et al.,
2007; Vaegter et al., 2011), but also has important biological func-
tions in other cell types, notably Schwann cells and oligodendrocytes
(Carter et al., 1996; Casaccia-Bonnefil et al., 1996; Gentry et al.,
2004). Sortilin is also widely expressed in neuronal and non-neuronal
cells (Petersen et al., 1997; Sarret et al., 2003); sometimes, sortilin is
also referred to as neurotensin receptor 3, as it is also a high-affinity
receptor for the neurotensin peptide (Mazella et al., 1998). Sortilin is
co-expressed with p75NTR in many sensory neurons that are not des-
tined for apoptosis, suggesting that the molecular makeup of a neuron
may dictate whether the cell responds to proNTs by apoptosis signal-
ing or with as yet unknown activities (Vaegter et al., 2011; Nykjaer
& Willnow, 2012). An important fact to appreciate about sortilin is
that, as its name implies, it was first identified as a receptor involved
in sorting intracellular cargoes between different membrane compart-
ments. In the context of sensory neurons and other central nervous
system cells, this fact means that only a small proportion of the total
sortilin will be available on the surface to bind ligands, and that the
presence of the receptor may be subject to strong regulation. More-
over, recent evidence suggests an important role for sortilin in facili-
tating anterograde Trk transport along neurites. Sortilin physically
interacts with Trk, and mice lacking sortilin expression show reduced
peripheral Trk targeting and a blunted response to mature neurotro-
phins (Vaegter et al., 2011). Another layer of complexity is added by
the fact that the extracellular domain of sortilin is also subject to
ADAM10-mediated shedding. In fact, significant amounts of soluble
sortilin can be detected in human serum samples, where it correlates
with receptor expression in the brain (Evans et al., 2011b). Whether
the ectodomain acts as a decoy receptor to scavenge proNTs in the
fluid phase or functions to increase its activity is currently not known.
However, it is noteworthy that soluble sortilin has been shown to pre-
vent proBDNF cleavage in vitro, suggesting that it may function as a
rheostat to balance synaptic input and regulate long-term depression
(proBDNF) and long-term potentiation (BDNF).
If proNTs play a functional role in peripheral or central sensitiza-
tion processes that underpin hyperalgesia, then it is important to
determine whether these factors are present in somatic sensory neu-
rons and/or their peripheral and central targets. Western blots from
skin, peripheral nerve and dorsal root ganglia indicate that proNGF
is actually quite abundant in all of these tissues (Reinshagen et al.,
2000; Anand, 2004; Bierl et al., 2005; Arnett et al., 2007). The
question arises of whether the proNTs are released under physiologi-
cal conditions associated with pain or hyperalgesia in inflammatory
or neuropathic conditions.
NGF and hyperalgesia: the linchpin theory
Hyperalgesia is defined as an increase in the felt intensity of a
noxious stimulus, usually following an injury or an inflammatory
process. Secondary hyperalgesia is the area of hypersensitivity
surrounding an injured area that cannot be signaled directly by
peripheral sensitization, as the afferents that innervate the secondary
area are not sensitized by the injury. This type of hyperalgesia is
thought to result from sensitization of central circuits to afferent
input coming from near the initial injury site (Treede et al., 1992;
Lewin & Moshourab, 2004). It is thought that strong activation of
nociceptors leads to rapid and long-lasting plasticity at synapses
between primary sensory neurons and dorsal horn neurons, and this
long-lasting change in synaptic strength can sustain hyperalgesia. It
was first noticed that rats that had been exposed to daily injections
of NGF were behaviorally more sensitive to mechanical and heat
stimuli than untreated animals (Lewin et al., 1993). Even a single
systemic injection of NGF (1 mg/kg body weight) produced pro-
found heat and mechanical hyperalgesia that lasted for several days.
Interestingly, heat and mechanical hyperalgesia appeared to be
mechanistically distinct, as heat hyperalgesia appeared within min-
utes, but mechanical hyperalgesia first became apparent at ~7 h after
the injection, and was maximal and sustained at 24 h (Lewin et al.,
1993). The fact that a single molecule, NGF, could set into train a
series of rapid functional changes with all of the hallmarks of hyper-
algesia, normally seen after a sterile inflammation, raised the obvi-
ous question of whether NGF was necessary for inflammatory
hyperalgesia. The use of NGF-blocking antibodies gave rise to a
new model of inflammatory hyperalgesia, in which NGF represents
a linchpin molecule that provides the key humoral link between
inflammation and the nociceptive sensory neurons that initiate and
sustain heat and mechanical hyperalgesia (Lewin & Mendell, 1993;
Lewin et al., 1994; Woolf et al., 1994). Later, the use of improved
molecular tools to sequester NGF, namely TrkA–IgG fusion proteins
that specifically bind endogenous NGF, was shown to ameliorate
heat and mechanical hyperalgesia associated with carrageenan-
evoked inflammation in rats (McMahon et al., 1995). The key find-
ing that blockade of NGF signaling reduces the impact of increased
NGF production in inflammatory conditions that is associated with
pain has now been repeated in many models (Pezet & McMahon,
2006; Mantyh et al., 2011).
In 1993, Lewin and Mendell proposed a mechanistic model illus-
trating the various ways in which increased NGF signaling could
produce heat and mechanical hyperalgesia in inflammatory condi-
tions. One key feature of this model was the idea that the mecha-
nisms that underlie the NGF-dependent heat hyperalgesia are
distinct from those that underlie the mechanical hyperalgesia (Lewin
& Mendell, 1993; Lewin et al., 1994). One important difference is
that NGF is capable of inducing extremely rapid changes in the
peripheral terminals of C-fibers that sensitize them to noxious heat
stimuli (Fig. 1A). Mechanical hyperalgesia, on the other hand,
seems to require the induction of changes in gene expression that
eventually lead to central sensitization, which maintains mechanical
hyperalgesia (Lewin & Mendell, 1993; Lewin et al., 1994). Below,
we will briefly review what is known of the molecular mechanisms
that underpin heat and mechanical hyperalgesia, and review how
proNT signaling may be involved.
NGF-dependent heat hyperalgesia: molecular
mechanisms
The availability of NGF in the skin was shown early on to regulate
the number of C-fibers that respond to noxious heat. Thus, decreas-
ing NGF levels with blocking antibodies reduced the number of
C-fibers that respond to heat, and raised NGF levels increased the
number of heat-sensitive C-fibers (Lewin & Mendell, 1994). These
early experiments demonstrated that the molecular basis of noxious
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heat transduction was itself a target of regulation by NGF. The regu-
lation of noxious heat transduction in single C-fibers in an inflam-
matory pain model was also shown to be dependent on NGF
(Koltzenburg et al., 1999). The very rapid NGF-induced heat hyper-
algesia was shown to be partly mediated by NGF-induced mast cell
degranulation, which can, in turn, release more NGF (Mazurek
et al., 1986; Lewin et al., 1994; Andreev et al., 1995). However,
subsequent studies have emphasized that most of the rapid heat
sensitization initiated by NGF takes place directly at the nociceptor
membrane (Fig. 1A). Thus, it was found that distinct isolated sen-
sory neurons possess an ionic inward current that is directly acti-
vated by noxious heat, sometimes referred to as Iheat (Cesare &
McNaughton, 1996). The Iheat current in isolated sensory neurons
can also be sensitized by algogens such as bradykinin (Cesare &
McNaughton, 1996; Cesare et al., 1999). There was great excite-
ment when the capsaicin-gated ion channel transient receptor poten-
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Fig. 1. Schematic representation of mechanisms that contribute to NGF hyperalgesia. (A) Possible mechanisms of peripheral sensitization that are dependent
on increased NGF production and release after injury and inflammation. Heat hyperalgesia (top) may be initiated locally by increased levels of NGF released
from keratinocytes and mast cells. NGF binds to high-affinity TrkA receptors to initiate rapid and local sensitization of nociceptors to heat that requires TRPV1
ion channels. Transduction currents may be increased (left current traces), leading to greater firing rates of nociceptors (middle action potentials in nociceptors)
in response to a heat stimulus (red) than that of resting nociceptors (gray). proNGF may also be released to interact with its receptors p75NTR and sortilin. The
signaling pathways initiated by proNGF are poorly understood. Increased NGF release after inflammation may also sensitize nociceptors to mechanical stimuli,
including increased transduction currents (left), which would increase firing rates in response to a standard mechanical stimulus (middle; gray, resting; red, sen-
sitized). Mechanical sensitization is long-lasting, and may develop over a longer time frame than heat hyperalgeia. NGF signaling may induce the increased bio-
genesis and transport of mechanosensitive ion channels (MECs) from the cell boy to the periphery in ‘transducosomes’. The role of proNGF signaling in this
sensitization event is poorly understood. (B) Possible mechanisms of central sensitization that are dependent on increased NGF production and release after
injury and inflammation. Signals initiated by NGF, or proNGF signaling, initiate increases in the expression of sensory neuron proteins in the cell body. Some
of the regulated proteins, such as BDNF, can affect the physiology of central spinal cord neurons to produce central sensitization; red traces represent the
responses of a sensitized dorsal horn neuron, and gray traces represent a resting neuron. proBDNF may also be released after sensitization, to influence synapses
in the dorsal horn. ASIC, acid-sensing ion channel; BK, Bradykinin; 5-HT, 5-hydroxytryptamine; IL-1, interleukin-1; PGE2, prostaglandin E2.
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tial cation channel subfamily V member 1 (TRPV1) was cloned by
Julius and colleagues, and this channel was also gated by heat in a
manner similar to Iheat (Caterina et al., 1997). Thus, the capsaicin
receptor and the noxious heat transduction channel appeared to be
one and the same thing. Mendell and Shu then showed that a single
short exposure of isolated sensory neurons to NGF (as well as NT-
4) greatly potentiated the capsaicin current amplitude measured just
minutes later (Shu & Mendell, 1999). NGF-induced heat hyperalge-
sia was later found to be dependent on the presence of TRPV1, as
NGF-induced hyperalgesia was not found in TRPV1/ mice (Chu-
ang et al., 2001). The persistence of NGF-induced heat hyperalgesia
in p75NTR/ mice suggested that this low-affinity receptor is not a
prerequisite for downstream sensitization (Bergmann et al., 1998).
As proNT signaling bypasses Trk receptors, this finding suggests
that proNGF is not involved in the generation of heat hyperalgesia
(Fig. 1A). However, one group has claimed that a recombinant
proNGF can, in fact, induce fast and long-lasting heat hyperalgesia
in mice (Watanabe et al., 2008). The proNGF protein that they used
was mutated to protect it from proteolysis, and was effective at the
doses normally used for local injection of NGF (Andreev et al.,
1995; Mills et al., 2013). The same group showed that blocking
antibodies directed against p75NTR ameliorated the heat hyperalge-
sia found after complete Freund’s adjuvant-induced inflammation,
and also ameliorated NGF-induced heat hyperalgesia (Watanabe
et al., 2008). If these authors are correct, then proNGF could
directly signal via sortilin–p75NTR to potentiate TRPV1-dependent
heat responses in the periphery. However, there is as yet no direct
genetic evidence that either p75NTR or sortilin is required for the
effects described for proNGF. The present consensus is that TRPV1
is a noxious heat-gated ion channel present in most noxious heat-
sensitive C-fibers, but its presence does not appear to be necessary
for these neurons to respond to noxious heat in vivo (Woodbury
et al., 2004). Recent studies have implicated new heat-activated ion
channels, such as anoctamin-1, a calcium-activated chloride channel,
and transient receptor potential cation channel subfamily M member
3 (TRPM3) as being required for heat transduction in nociceptors
(Vriens et al., 2011; Cho et al., 2012). However, it is not yet known
whether NGF-dependent heat hyperalgesia and nociceptor sensitiza-
tion are dependent on either anoctamin-1 or TRPM3. The absolute
requirement for TRPV1 for NGF-dependent heat hyperalgesia and
nociceptor sensitization has led many workers to use increased
TRPV1 activity as a molecular surrogate for sensitization. Thus,
capsaicin has often being used, rather than heat, to activate TRPV1.
Work on dorsal root ganglion (DRG) neurons identified protein
kinase activity as being responsible for the sensitization brought
about by NGF, with protein kinase C and phosphoinositide 3-kinase
(PI3K) being the most likely mediators (Shu & Mendell, 1999; Bon-
nington & McNaughton, 2003). Whereas protein kinase C acts pre-
dominantly via direct phosphorylation of TRPV1 (Numazaki et al.,
2002), the PI3K pathway has multiple steps: following TrkA auto-
phosphorylation at Tyr760, PI3K is activated, and in turn activates
Src kinase, a non-receptor tyrosine kinase, that subsequently phos-
phorylates Tyr200 on TRPV1, resulting in translocation to the
plasma membrane and increased membrane expression (Zhang
et al., 2005; Stein et al., 2006). The fact that a translocation of
TRPV1 channels from the cytoplasmic compartment to the plasma
membrane is involved in sensitization is intriguing in the context of
the role of sortilins in sorting and signaling. Although sortilin defi-
ciency by itself does not impact on heat-induced pain or mechanical
sensation, on the genetic background of p75NTR knockout both
nociception and tactile sensation are severely impaired (Vaegter
et al., 2011). As mice lacking sortilin or p75NTR are unable to
respond to proNT stimulation, the sensory deficits in the double-
knockout mouse are most likely to be accounted for by reduced Trk
signaling from mature neurotrophins. Hence, p75NTR deficiency
reduces the affinity and specificity of neurotrophins for their cognate
Trk receptors (Chao, 2003), and sortilin reduces anterograde Trk
transport and exposure on the plasma membrane. Whether sortilin
may also target TRPV1 to the cell surface is unknown, but it is
noteworthy that sortilin is required for translocation of vesicles con-
taining glucose transporter type 4 from the intracellular compartment
to the plasma membrane (Kandror & Pilch, 2011). It would, of
course, be interesting to determine in cellular systems whether sorti-
lin or p75NTR participates in the fast sensitization events. NGF-
induced heat hyperalgesia is rapid in onset in vivo, but is also very
long-lasting, and it has been suggested that NGF can also enhance
TRPV1 expression levels via the Ras–mitogen-activated protein
kinase pathway (Ji et al., 2002), which could contribute to persistent
heat hyperalgesia. It should, however, be noted that there is good
evidence that persistent heat hyperalgesia following inflammation or
NGF elevation may also be dependent on central sensitization
(Fig. 1B).
The fact that TRPV1 is necessary for sensitization, but not for the
transduction of noxious heat by nociceptors, is an important fact that
requires further investigation (Woodbury et al., 2004; Koerber
et al., 2010). One could speculate that freshly phosphorylated
TRPV1 or newly inserted TRPV1 molecules in turn directly interact
with candidate heat-gated channels, such as anoctamine-1 or
TRPM3, to produce sensitization. Alternatively, TRPV1 may itself
have a signaling function that is required for the sensitization of heat
transduction. In order to answer these questions, definitive identifica-
tion of the molecule(s) necessary for heat transduction will be
required. The signaling pathways that converge onto TRPV1 from
TrkA activation are also engaged by other growth factor receptors,
such as c-Ret together with its co-receptors GFRa2 and GFRa3
(Stucky et al., 2002; Malin et al., 2006), which are preferentially
activated by neurturin and artemin, respectively (Baloh et al., 2000;
Bespalov & Saarma, 2007). Neurturin signaling, in particular, may
be like NGF signaling, in the sense that it regulates the number of
heat-sensitive neurons among the subpopulation of isolectin-B4-
positive sensory neurons that, in the adult, lack TrkA receptors
(Molliver et al., 1997; Stucky & Lewin, 1999; Stucky et al., 2002).
Curiously, the sortilin-related receptor SorLA was recently demon-
strated to be critically involved in GFRa and c-Ret sorting and
signaling (Glerup et al., 2013). The receptor tyrosine kinase c-Kit is
the receptor for stem cell factor (SCF), and was recently found to be
expressed by a subpopulation of noxious heat-sensitive nociceptors
(Milenkovic et al., 2007). It has been shown that SCF–c-Kit signal-
ing is necessary to maintain nociceptor heat sensitivity, and that
SCF can, like NGF, sensitize Iheat and produce rapid but short-last-
ing heat hyperalgesia in a TRPV1-dependent manner (Milenkovic
et al., 2007). Interestingly, in the case of glial cell line-derived neu-
rotrophic factor-like ligands and SCF, only heat sensitization has
been reported, but mechanical hyperalgesia was absent [but see
(Albers et al., 2006)].
Mechanisms of NGF-dependent mechanical
hyperalgesia
Mechanical hyperalgesia is the symptom that most concerns patients
with painful conditions caused by inflammation or injury. It is very
striking to observe that a short burst of elevated NGF can be suffi-
cient to induce mechanical hyperalgesia that can last for days or
even weeks in rodents and humans (Lewin et al., 1993; Petty et al.,
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1994). Systemic or local injection of the NGF peptide is unlikely to
lead to sustained TrkA activation, as this small polypeptide would
be rapidly degraded by extracellular proteases after injection. Thus,
a pulse of NGF is sufficient to set in train a series of events that
sustain mechanical hyperalgesia, often for days (Fig. 1A and B).
NGF can produce long-lasting changes in gene expression in adult
sensory neurons, and the first genes shown to be controlled by NGF
were those encoding the neuropeptides substance P (SP) and calcito-
nin gene-related peptide (CGRP; Lindsay & Harmar, 1989). Release
of neuropeptides from sensory neurons may modulate the strength
of spinal cord synapses (Seybold, 2009); however, mice with a tar-
geted mutation of the tachykinin-1 gene coding for SP do not show
deficits in inflammation-induced mechanical hyperalgesia (Cao
et al., 1998). Thus, considering that NGF is required for inflamma-
tion-induced mechanical hyperalgesia, it appears to be unlikely that
SP is a major central mediator. Studies on mice lacking a second
major neuropeptide, CGRP, expressed in TrkA-positive sensory neu-
rons (Molliver et al., 1997), have indicated broad deficits in inflam-
matory hyperalgesia, including mechanical hyperalgesia (Salmon
et al., 2001). In their study on proNGF in inflammatory pain,
Watanabe et al. (2008) described p75NTR-dependent increases in
CGRP levels in the DRG. It is, however, unclear whether these
effects are also dependent on sortilin receptors. Until now, there has
been no concrete indication that changes in gene expression can be
specifically regulated by p75NTR–sortilin signaling (Fig. 1A and
B). The question naturally arises of whether exogenous proNGF can
produce mechanical hyperalgesia and, if so, what mechanisms are
involved. Recently, it was reported that high doses of recombinant
proNGF could provoke significant mechanical hyperalgesia in mice,
starting 5 h after local injection into the skin; later time points were
not examined (Capsoni et al., 2011). The authors used a recombi-
nant unmodified proNGF molecule that might conceivably be pro-
cessed to mature NGF in the extracellular space. It is thus possible,
but not proven, that the mechanical hyperalgesia observed resulted
from activation of the classic TrkA pathway or occurred via
sortilin–p75NTR signaling.
Neurotrophins were traditionally thought of as being produced by
the targets of sensory neurons, but it became apparent from develop-
mental studies that many sensory neurons can actually express and
produce neurotrophins (Ernfors et al., 1990). It was therefore strik-
ing when it was discovered that BDNF is normally produced by a
subset of TrkA-positive nociceptors, and that the number of TrkA-
positive neurons making this factor is dramatically increased by
increased NGF levels (Apfel et al., 1996; Michael et al., 1997).
Indeed, BDNF was shown to be released by activity in sensory neu-
rons, and its release was enhanced by the elevated NGF levels that
follow inflammation (Balkowiec & Katz, 2000; Lever et al., 2001).
Thus, increased peripheral NGF levels lead to increased production
and release of BDNF from the central synapses of nociceptors in the
spinal cord, and this may be critical for certain central sensitization
events, especially those involving N-methyl-D-aspartate (NMDA)
receptors (Kerr et al., 1999). Direct electrophysiological evidence
demonstrating that BDNF can rapidly potentiate transmission at syn-
apses formed by nociceptors was provided by Mendell and col-
leagues (Garraway et al., 2003). The effects of mature BDNF on
spinal synapses is rapid, and probably occurs via both presynaptic
and postsynaptic TrkB receptors; such effects have been shown to
occur via phosphorylation of NMDA receptor subunits (Kerr et al.,
1999; Heppenstall & Lewin, 2001; Garraway et al., 2003). It is
clear that the classic pathways activated by BDNF are eventually
responsible for the phosphorylation of NMDA receptor subunits
such as NR1, which eventually mediate some forms of central
sensitization (Pezet & McMahon, 2006; Fig. 1B). One complication
in examining the central sensitization effects of BDNF is that this
factor is also produced within the brain and spinal cord. Further-
more, the production and release of BDNF or proBDNF may be
controlled by many factors. For example, it has been proposed that,
when activated, spinal microglia cells may release BDNF, which, in
turn, can modulate the excitability of dorsal horn neurons. The mod-
ulation of the anion gradient in lamina I projection neurons, possibly
via the modulation of KCC2 (a potassium chloride co-transporter),
can lead to a shift in the reversal potential for anions such as chlo-
ride, which makes normally hyperpolarizing inputs from inhibitory
interneurons either ineffective or even depolarizing (Coull et al.,
2005). This type of BDNF effect is thought to be particularly rele-
vant for sustaining neuropathic pain. Whether sortilin is involved in
the BDNF-dependent regulation of KCC2 is currently unknown, but
it is thought-provoking that sortilin physically interacts with and is
responsible for lysosomal targeting of the related cation-coupled
chloride co-transporter NCC2 in the kidney (Zhou et al., 2010).
Global deletion of the gene encoding BDNF leads to early post-
natal lethality, which has made the study of BDNF’s role in the
adult nervous system more difficult (Carroll et al., 1998). Neverthe-
less, studies using isolated spinal cords from young neurotrophin
gene mutant mice have shown that the plasticity of ventral root
potentials, which reflects C-fiber drive flexion reflexes, is selectively
attenuated in the absence of BDNF, but not in the absence of NT-4
(Heppenstall & Lewin, 2001). A systematic examination of pain-
related behaviors in BDNF heterozygote mutant mice also indicated
that even reduced gene dosage of this important factor can lead to
deficits in acute noxious heat sensitivity and reduced pain behaviors,
e.g. in the formalin test (MacQueen et al., 2001). An elegant genetic
study using mice in which the BDNF gene was selectively deleted
in nociceptive sensory neurons showed that BDNF is required for
normal heat hyperalgesia following inflammation (Zhao et al.,
2006). However, the authors did not definitively address the ques-
tion of whether NGF-induced mechanical hyperalgesia depends on
sensory neuron-derived BDNF. However, direct injection of NGF
into skeletal muscle did not provoke mechanical hyperalgesia in this
model, which, in common with other studies, suggests that elevated
muscle NGF provokes central sensitization (Lewin et al., 1992;
Zhao et al., 2006). In summary, it seems that at least a proportion
of the sustained heat hyperalgesia initiated by NGF may be sus-
tained by central sensitization driven by BDNF and subsequent
phosphorylation of postsynaptic NMDA receptors (Lewin et al.,
1994; Zhao et al., 2006).
It is now clear that many neurons can, in fact, synthesize and
release proBDNF, as well as mature BDNF (Pang et al., 2004; Teng
et al., 2005; Woo et al., 2005). Sensory neurons contain proBDNF
and transport proBDNF; it therefore appears likely that both proB-
DNF and mature BDNF production could be increased when NGF
levels are elevated, e.g. following inflammatory insults (Wang et al.,
2006; Fan et al., 2008). Thus, the phenotypic consequences of
BDNF deletion in sensory neurons are potentially also attributable
to loss of proBDNF; there are, as yet, no data indicating that noci-
ceptors actually release proBDNF at central synapses (Fig. 1B).
Recent reports have shown that activated microglia can release
proNTs (Srinivasan et al., 2004), and that stimulation of sortilin on
microglia can promote their migration and mediate their ability to
produce and secrete cytokines (Martin et al., 2003; Dicou et al.,
2004). Indeed, it has also been reported that sortilin can facilitate
proNT secretion, as exemplified by proBDNF (Chen et al., 2005),
and exogenous proNGF itself may have an activating effect on hip-
pocampal glia (Guo et al., 2013). The evidence so far suggests that
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neuropathic pain does not depend on increased or decreased NGF
signaling (Pezet & McMahon, 2006), but the activation of spinal
microglia is central to the initiation of neuropathic symptoms (Tsuda
et al., 2013). Thus, activated microglia injected into the spinal cord
are by themselves sufficient to induce symptoms of neuropathic
pain, such as profound mechanical allodynia (Tsuda et al., 2003).
The factor or factors that signal nerve injury to activate spinal cord
microglia are, at present, unknown. Inhibition of microglial activa-
tion has also been promoted as a potential therapy for neuropathic
pain, with drugs such as minocycline, a second-generation tetracy-
cline, showing efficacy in neuropathic pain models and suppressing
microglial activation (Raghavendra et al., 2003). Interestingly, the
same drug was recently shown to inhibit the production of proNGF
by activated microglia after spinal cord injury (Yune et al., 2007).
Thus, there is indeed indirect evidence that proNTs may be involved
in the pathophysiology of neuropathic pain. There are some reports
of changes in the levels of proNGF in peripheral tissues associated
with nerve injury or in neuropathy models, but the findings are
actually contradictory (Yiangou et al., 2002; Peleshok & Ribeiro-
da-Silva, 2012). It is thus conceivable that proNTs could play a role
at the critical transition point that converts nerve injury into changes
in spinal circuitry that sustain neuropathic pain symptoms (Tsuda
et al., 2013).
A key difference between NGF-induced heat and mechanical
hyperalgesia lies in the often radically different time courses that
these phenomena display. Pure NGF-dependent hyperalgesia has, in
the last few years, been increasingly studied in human subjects, as
the injection of small amounts of NGF into the muscle or skin offers
an excellent model for both short-term and long-term sensitization,
while bypassing inflammatory processes. During the first phase I
safety trials of recombinant human NGF (rhNGF), it was quickly
realized that human subjects experienced local soreness, as well as
very long-lasting deep tissue hyperalgesia, or myalgia following
rhNGF injection (Petty et al., 1994). In this first human study, dose-
dependent myalgia and hyperalgesia was observed to last for up to
7 weeks following a single injection. As in animal models, the
mechanisms by which NGF produces mechanical hyperalgesia in
humans will probably differ between very early and late phases.
Recent studies in humans showed that hyperalgesia, as measured
with the use of pressure pain threshold or pinprick sensitivity, first
appears after 7 days, and peaks 21 days after an intradermal rhNGF
injection (Rukwied et al., 2010, 2013; Obreja et al., 2011a;
Weinkauf et al., 2012, 2013). Much more rapid and pronounced
hyperalgesia has been noted following injection of rhNGF into
human muscles or muscle fascia (Svensson et al., 2003, 2008;
Andersen et al., 2008; Deising et al., 2012), and this hypersensitiv-
ity differs in several important respects from the NGF-induced
mechanical hyperalgesia observed in the skin. First, mechanical hy-
peralgesia is observed within a few hours of the injection, and the
pressure pain hypersensitivity extends well beyond the area of the
initial injection (Svensson et al., 2003, 2008; Andersen et al., 2008;
Deising et al., 2012). As a rule, the muscle hypersensitivity follow-
ing rhNGF injection is also observed to subside within a few days
of injection, in marked contrast to the very long-lasting hyperalgesia
that follows a skin injection. In the skin model, the available studies
have noted that the mechanical hyperalgesia remains strictly
restricted to the area of the initial rhNGF injection (Rukwied et al.,
2010; Obreja et al., 2011a; Weinkauf et al., 2012), which is a
strong indication that a peripheral sensitization process may be
involved (Treede et al., 1992; Lewin & Moshourab, 2004).
In animal models, systemic injection of NGF provoked mechani-
cal hyperalgesia that first appeared between 1 h and several hours
after the injection, and persisted for days (Lewin et al., 1993, 1994;
Thompson et al., 1995; Mills et al., 2013). Local skin injection of
NGF in rats also provoked a localized mechanical hyperalgesia that
persisted for days (Mills et al., 2013). It appears that elevated NGF
in skeletal muscle can sensitize muscle afferents to mechanical stim-
uli, but the evidence from human and animal studies suggests that
secondary hyperalgesia is a prominent feature of this model, which
involves central sensitization (Lewin et al., 1992; Hoheisel et al.,
2007, 2013). The observation that elevated NGF in the skin does
not appear to provoke secondary mechanical hyperalgesia suggests
that nociceptor sensitization plays a prominent role in this model
(Fig. 1A).
Clear direct evidence that cutaneous nociceptors are sensitized to
mechanical stimuli after exposure to elevated NGF in vivo has been
missing, until recently (Hirth et al., 2013). Many nociceptors are
polymodal, meaning that they are activated by more than one
modality of noxious stimulus; for example, C-fibers activated by
noxious mechanical and heat stimuli are termed C-mechanoheat
units. With this classification scheme, it is possible to record the
following additional types of nociceptor in human skin by the use
of microneurography techniques: C-mechanosensitive, C-mechano-
sensitive and cold, C-mechanosensitive heat and cold, C-mechano-
insensitive and heat-insensitive (C-MiHi) cold, and finally C-low
threshold mechanoreceptors (Lewin & Moshourab, 2004). Broadly,
the same types of nociceptors have been recorded in the skin of rats
and mice (Lewin & Mendell, 1994; Koltzenburg et al., 1997), but
there appear to be consistent species differences, particularly in the
incidence of each fiber type. In particular, C-MiHi fibers, identified
in sub-human primates as mechanically insensitive afferents, appear
to be rare in rodents (Handwerker et al., 1991; Meyer et al., 1991;
Kress et al., 1992; Lewin & Mendell, 1994), but are relatively com-
mon in human hairy skin (Schmidt et al., 1995; Weidner et al.,
1999). Several studies have strongly implicated C-MiHi fibers in
peripheral sensitization processes; thus, these fibers can rapidly
acquire mechanosensitivity when stimulated with strong algogens.
Recent studies by Schmelz and colleagues have shown that C-MiHi
units are also present in the skin of the pig, which they have
claimed may be a more suitable animal model for human nocicep-
tors (Obreja & Schmelz, 2010). One feature of C-MiHi fibers
recorded in humans and in pigs is that they show a very strong and
prominent activity-dependent slowing of their conduction velocity
(Weidner et al., 1999; Obreja et al., 2011b; Hirth et al., 2013).
Thus, the higher the firing rate, the longer it takes for the action
potentials to reach the first spinal synapses. Strikingly, cutaneous
NGF elevation in pigs selectively reduced the magnitude of activity-
dependent slowing as well as reducing the number of conduction
failures at a moderate stimulation frequency of 2 Hz (Obreja et al.,
2011a,b). Patients experienced more pain when cutaneous electrical
stimuli were employed at the height of the hyperalgesia induced by
local intradermal injection of rhNGF. The more reliable initiation
and propagation of action potentials in nociceptors under these cir-
cumstances may be physiologically relevant, as electrical stimulation
could be seen as analogous to the driving depolarization produced
by the opening of transduction channels. In a very recent study, Hir-
th et al. (2013) actually provide good evidence for local nociceptor
sensitization that is robust only 21 days after the initial NGF injec-
tion in a pig model. Essentially, the authors show that, at this point,
a significant and large proportion of formerly C-MiHi fibers are now
very sensitive to mechanical stimuli; however, the suprathreshold
coding properties of these fibers was not examined. There are a cou-
ple of interesting features of these findings: one is the extremely
long period of time that it apparently takes before sensitization of
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nociceptors is overt following local NGF exposure; and second,
why does it takes so long for NGF-mediated signaling to induce
unmasking of mechanosensitivity whereby acute exposure to strong
algogens can unsilence C-MiHi fibers with a very rapid time course
(Schmidt et al., 1995)? The human psychophysical data are clear
with regard to the fact that acute elevation of NGF in muscle, as
opposed to skin, can produce rapid sensitization, but even here there
are few data to indicate why this may be the case. In one study in
rats, NGF was injected directly into the muscle, and led to apparent
activation of C-fiber afferents in the muscle, but did not lead to an
acute sensitization of muscle C-fibers to mechanical stimuli (Hohei-
sel et al., 2005). In common with the innervation of the viscera
(McMahon & Koltzenburg, 1990), normal skeletal muscle is inner-
vated by a large number of C-fibers that are insensitive to mechani-
cal stimuli (Jankowski et al., 2013). It is not clear at present
whether NGF or proNGF can also lead to unmasking of mechano-
sensitivity in deep tissue nociceptors such as those innervating
skeletal muscle.
Cell biology of long-lasting sensitization induced by
neurotrophins
The cell biology of DRG sensory neurons is unusual; these neurons
accomplish two fundamentally different tasks at their central and
peripheral endings, which are separated by an enormous distance.
Synaptic transmission and precise connectivity are established at the
spinal cord end, and transduction is accomplished at specialized end-
ings in the periphery. In between, located at approximately two-
thirds of the distance between these points, is the cell body, which
must provide specialized proteins, membranes and organelles that
are sometimes differentially distributed between the peripheral and
central branches (Garcıa-A~noveros et al., 2001). The retrograde and
local signal transduction events initiated by NGF have been studied
for decades, and it is clear that NGF can exert some effects locally
in the periphery, and that many effects are transported and propa-
gated to the cell body via the so-called signaling endosome (Campe-
not & MacInnis, 2004).
The proNT co-receptor sortilin has recently been found to play an
important role in the trafficking of TrkA-bearing vesicles in sensory
neurons axons in vivo. Thus, in the absence of sortilin receptors,
TrkA-positive vesicles are transported much less in the anterograde
direction than in the wild type (Vaegter et al., 2011). The reduced
transport, especially of the 140-kDa glycosylated TrkA molecule,
reduced the signaling efficiency in vivo, with weaker activation of
phosphorylated extracellular signal-related kinase 1/2, presumably
because fewer TrkA receptors reached the plasma membrane. Sortilin
was shown to bind directly to all three of the high-affinity neurotro-
phin receptors – TrkA, TrkB, and TrkC – and probably has a role in
regulating receptor distribution in all neurons that respond to neurotro-
phins (Vaegter et al., 2011). It was especially striking in this respect
that complete deletion of the sortilin gene dramatically exacerbated
the phenotype of TrkA deficiency, as TrkA+/ mice were not born in
the absence of the sortilin receptor (Vaegter et al., 2011). TrkA-posi-
tive vesicles need to reach the peripheral endings of sensory axons to
respond to physiological NGF levels, and it is also in peripheral tis-
sues that NGF is elevated during inflammatory conditions. However,
sortilin/TrkA-containing vesicles are not the only vesicles whose
cargo is also destined to become concentrated at the peripheral end-
ings. Sensory endings possess a robust and stable transduction appara-
tus equipped to transduce mechanical signals in different ways in
different sensory subtypes. Indeed, there are now examples of ion
channel proteins that are specifically targeted to the peripheral endings
of specific mechanoreceptor types, e.g. the potassium channel KCNQ4
in rapidly adapting mechanoreceptors (Heidenreich et al., 2012). How
is this exquisite spatial and functional segregation achieved? The
transport of proteins involved in the transduction and transformation
of sensory signals at the peripheral endings of sensory neurons is very
poorly understood, but represents a clear potential target for NGF
modulation of afferent mechanosensitivity. STOML3 is the only
protein known to participate directly in fast mechanotransduction, a
process that could be directly modulated by inflammatory mediators
that sensitize nociceptors to mechanical stimuli (Wetzel et al., 2007).
We found that STOML3 is localized to a highly mobile and molecu-
larly distinct transport vesicle within cultured sensory neuron axons
(Lapatsina et al., 2012). These vesicles are capable of co-transporting
the related stomatin-domain protein, stomatin, together with each of
the acid-sensing ion channel family members found in the DRG (La-
patsina et al., 2012). Members of the Rab GTPase family of protein
are involved in controlling the organization and identity of different
membranous compartments within cells and neurons. For example,
Rab5 and Rab7 are localized to signaling endosomes that are thought
to retrogradely transport neurotrophin signals from the periphery to
the cell body (Deinhardt et al., 2006). Interestingly, the STOML3-
containing vesicles do not form part of the signaling endosome pool,
as they are Rab5-negative but Rab11-positive. Rab11-positive vesicles
have been characterized as composing a slowly recycling endocytic
compartment, and may be transported predominantly anterogradely in
sensory neurons (Asca~no et al., 2009; Eva et al., 2010). Indeed, gain
or loss of function Rab11 mutants radically change vesicle behavior,
but these compartments still contain STOML3 (Lapatsina et al.,
2012). The STOML3 vesicle is obviously enriched in proteins that are
destined to function in transduction at the peripheral endings of sen-
sory neurons, and so we have proposed naming these vesicles ‘trans-
ducosomes’. The localization of sortilin with TrkA-positive vesicles
suggests that the ‘transducosome’ is distinct from anterogradely trans-
ported TrkA-containing vesicles; however, this idea has not been
tested directly. Ex vivo recordings from sensory afferents innervating
the skin have demonstrated that transduction of mechanical stimuli at
the peripheral endings of sensory neurons is very stable for many
hours in the absence of a connection to the cell body. Indeed, early
nerve injury experiments provided evidence that anterogradely trans-
ported proteins are first incorporated into cut endings to confer me-
chanosensitivity at a speed that is consistent with their transport
distally via fast axonal transport (Koschorke et al., 1994). The stabil-
ity of the transduction complexes at sensory endings is likely to be a
function of three main factors: the number of ‘transducosomes’ that
arrive per unit of time; the propensity of such vesicles to fuse with the
membrane and deliver functional transduction proteins; and, finally,
the stability of existing transduction complexes. If this model is cor-
rect, it is obvious that the ability of a sensory neuron to become sensi-
tized to mechanical stimuli, or indeed to become newly mechanically
sensitive, can be regulated at the levels of vesicle transport, fusion, or
endocytosis of, or recovery of, spent transduction complexes
(Fig. 1A). It is clear from the time course of fast mechanical hyperal-
gesia (hours) that local action of NGF might regulate the steps out-
lined above, but the molecular details are still completely unclear.
Long-lasting mechanical hyperalgesia could be sustained by signals
that are carried by signaling endosomes to initiate a cell body
response, which may or may not include new gene expression, but
would change the transduction process via the transport of novel, per-
haps modulatory, subunits to the mechanotransducer. Thus, in the
context of nociceptor sensitization, it is tempting to consider the
TrkA/sortilin vesicle as the signaling part, and the ‘transducosome’ as
a potential long-term effector. We recently identified a large extracel-
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lular tether protein that appears to be required for efficient and fast
transduction in mechanoreceptors and many nociceptors (Hu et al.,
2010). It is obvious that the transport of this protein could provide a
way to ‘unsilence’ nociceptors, but this hypothesis can only be tested
once the identity of this protein is known.
NGF, proNTs, and sensory neuropathies
It is clear that the NGF elevation that accompanies inflammation ini-
tiates a complex series of events, some of which are local and fast,
and others of which are global and long-lasting. Anti-NGF therapy is
remarkably effective in a broad variety of pain conditions, ranging
from muscle pain to bone cancer pain (Mantyh et al., 2010; Jime-
nez-Andrade et al., 2011). This remarkable efficacy of anti-NGF
therapy is probably attributable to the broad range of molecular
events that are set into motion by elevated NGF levels in a variety
of different tissues. New molecular tools, such as blocking antibodies
specific for proNTs (Paoletti et al., 2012), or genetic models such as
sortilin-null mutant mice (Jansen et al., 2007; Vaegter et al., 2011),
may reveal distinct or overlapping roles for this distinct signaling
system in pain. There are, in fact, intriguing hints in the literature
that proNGF and proBDNF signaling may play an important role in
the pathophysiology of neuropathic pain that requires microglial acti-
vation. It is clear that mature NGF is strongly implicated in hyperal-
gesia following inflammation, but the evidence is much more
equivocal for a role in the pathophysiology of neuropathic pain. This
is despite the long-standing hypothesis that reduced NGF levels in
the skin may be involved in the pathophysiology of neuropathic pain
that is associated with diabetic neuropathy (Anand, 2004). In this
context, it is particularly interesting that the loss of p75NTR and sor-
tilin function leads to very severe late-onset sensory neuropathy in
mice (Vaegter et al., 2011). Loss of function mutations in the genes
encoding the TrkA receptor or its ligand NGF are classic causes of
the rare and severe condition of congenital insensitivity to pain (Indo
et al., 1996; Einarsdottir et al., 2004; Carvalho et al., 2011).
A recent report described a novel loss of function mutation in the
human NGF gene that leads to congenital pain insensitivity and an
apparently non-functional NGF, because it is defectively processed
and accumulates as proNGF (Larsson et al., 2009). Biochemical
studies on NGF and proNGF carrying this mutation indicate that
they are either without biological activity in vivo or are less effective
at binding their receptors (Covaceuszach et al., 2010; Capsoni et al.,
2011). Recent genetic and functional studies have strongly impli-
cated sortilin and related receptors as key molecules that govern the
severity of Alzheimer’s disease (Carlo et al., 2013; Gustafsen et al.,
2013). Given the importance of this receptor in proNT and neurotro-
phin signaling, it is tempting to speculate that new variants in the
sortilin–p75NTR signaling pathway could be associated with human
susceptibility to neuropathic and inflammatory pain.
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